| scholarly article | Q13442814 |
| P50 | author | Jonel Trebicka | Q41068089 |
| P2093 | author name string | T Sauerbruch | |
| C Stark | |||
| J Heller | |||
| M Hennenberg | |||
| A Z Kohistani | |||
| P2860 | cites work | Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction | Q24653656 |
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase | Q28582593 | ||
| Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis | Q46967668 | ||
| Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats | Q46985848 | ||
| Anesthetic influences on regional hemodynamics in normal and hemorrhaged rats. | Q51836243 | ||
| Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. | Q53545899 | ||
| Measurement of organ blood flow with coloured microspheres in the rat | Q72641928 | ||
| A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth | Q73876502 | ||
| Both Ca2+ -dependent and -independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine | Q79156898 | ||
| Vascular dysfunction in human and rat cirrhosis: role of receptor-desensitizing and calcium-sensitizing proteins | Q79671118 | ||
| Phase II study of sorafenib in patients with advanced hepatocellular carcinoma | Q80112177 | ||
| Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase | Q29615195 | ||
| Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. | Q30304611 | ||
| Post-transcriptional down-regulation of ROCKI/Rho-kinase through an MEK-dependent pathway leads to cytoskeleton disruption in Ras-transformed fibroblasts | Q33953392 | ||
| Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow | Q34305850 | ||
| Cytokine receptors and signaling in hepatic stellate cells | Q34391388 | ||
| Vascular mediators in the injured liver | Q35033793 | ||
| When 6 is 9: 'uncoupled' AT1 receptors turn signalling on its head. | Q35953152 | ||
| Portal hypertension: from bedside to bench. | Q36066757 | ||
| Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. | Q36066761 | ||
| Rho kinases in cardiovascular physiology and pathophysiology | Q36399309 | ||
| Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease. | Q36526640 | ||
| Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system | Q36548154 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors | Q36678037 | ||
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors | Q36807146 | ||
| Splanchnic and systemic vasodilatation: the patient | Q36988061 | ||
| Splanchnic and systemic vasodilation: the experimental models | Q36988066 | ||
| Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials | Q37008436 | ||
| Cardiovascular complications of cirrhosis. | Q37056007 | ||
| Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 | ||
| Mechanisms of extrahepatic vasodilation in portal hypertension. | Q37150625 | ||
| Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. | Q40068184 | ||
| Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. | Q40192837 | ||
| Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature | Q40270911 | ||
| Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury | Q42439505 | ||
| H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter. | Q42510616 | ||
| Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis | Q42667685 | ||
| Guide to Receptors and Channels (GRAC), 3rd edition | Q43088119 | ||
| A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced hepatic fibrosis in rats | Q43631422 | ||
| Differential expression of platelet-derived growth factor α- and β-receptors on fat-storing cells and endothelial cells of rat liver | Q43736383 | ||
| Inhibitory effect of Y-27632, a ROCK inhibitor, on progression of rat liver fibrosis in association with inactivation of hepatic stellate cells | Q43780882 | ||
| MEK mediates v-Src-induced disruption of the actin cytoskeleton via inactivation of the Rho-ROCK-LIM kinase pathway | Q43993777 | ||
| Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells | Q44493287 | ||
| Fasudil hydrochloride hydrate, a Rho-kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase activity in hepatic stellate cells | Q46584631 | ||
| Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats | Q46719870 | ||
| Defective endothelial nitric oxide synthase signaling is mediated by rho-kinase activation in rats with secondary biliary cirrhosis | Q46826996 | ||
| Mechanisms of hypertension associated with BAY 43-9006. | Q46919074 | ||
| Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma | Q46937457 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | portal hypertension | Q124604 |
| P304 | page(s) | 258-270 | |
| P577 | publication date | 2009-03-26 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis | |
| P478 | volume | 157 |
| Q43060938 | A case of variant angina in a patient under chronic treatment with sorafenib. |
| Q54314567 | Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents. |
| Q28068579 | Cancer and liver cirrhosis: implications on prognosis and management |
| Q50973238 | Canonical hedgehog signalling regulates hepatic stellate cell-mediated angiogenesis in liver fibrosis. |
| Q35842553 | Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats |
| Q30465168 | Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis |
| Q45753521 | Desensitization of G-protein-coupled receptors induces vascular hypocontractility in response to norepinephrine in the mesenteric arteries of cirrhotic patients and rats |
| Q34446521 | Future therapy of portal hypertension in liver cirrhosis - a guess |
| Q91854552 | Fuzhenghuayu Decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis |
| Q38334016 | Hagen-Poiseuille's law: The link between cirrhosis, liver stiffness, portal hypertension and hepatic decompensation |
| Q50559019 | Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis. |
| Q90648282 | Hepatic microcirculation and mechanisms of portal hypertension |
| Q38759447 | Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights |
| Q37783754 | Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension? |
| Q42468400 | Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. |
| Q49196634 | Ligand Activation of PPARγ by Ligustrazine Suppresses Pericyte Functions of Hepatic Stellate Cells via SMRT-Mediated Transrepression of HIF-1α. |
| Q26797581 | Management of Hepatocellular Carcinoma in Cirrhotic Patients with Portal Hypertension: Relevance of Hagen-Poiseuille's Law |
| Q55278061 | Managing portal hypertension in patients with liver cirrhosis. |
| Q50146306 | Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase |
| Q26772800 | New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials |
| Q36121721 | Novel Rat Model of Repetitive Portal Venous Embolization Mimicking Human Non-Cirrhotic Idiopathic Portal Hypertension. |
| Q38680437 | Novel treatment options for portal hypertension |
| Q34992341 | Paediatric cholestatic liver disease: Diagnosis, assessment of disease progression and mechanisms of fibrogenesis. |
| Q92062549 | Procyanidin B2 inhibits the activation of hepatic stellate cells and angiogenesis via the Hedgehog pathway during liver fibrosis |
| Q86187033 | Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis |
| Q48635527 | Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis |
| Q43273262 | Sorafenib in advanced hepatocellular carcinoma |
| Q48599791 | Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. |
| Q84127318 | Sorafenib-associated multivessel coronary artery vasospasm |
| Q34352802 | Targeting the PDGF signaling pathway in the treatment of non-malignant diseases |
| Q36929326 | The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma |
| Q36180467 | The chinese herbal decoction danggui buxue tang inhibits angiogenesis in a rat model of liver fibrosis |
| Q54342105 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study. |
| Q59799447 | The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension |
| Q37676226 | Toxicity of sorafenib: clinical and molecular aspects |
| Q42472251 | Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. |
| Q28068710 | Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis? |
| Q33643380 | Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling |
| Q37895616 | What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? |
Search more.